Scholar Rock Holding Corporation Common Stock
SRRKScholar Rock Holding Corporation (SRRK) is a biopharmaceutical company focused on discovering and developing medicines that target growth factors involved in serious medical conditions. Its approach emphasizes precision medicine aimed at diseases such as fibrosis and cancer, utilizing its proprietary drug discovery platform to develop first-in-class therapeutics.
Company News
Commodore Capital fully exited its position in Scholar Rock, selling approximately 1.5 million shares in Q3, representing a $51 million transaction. The biotech company is preparing to resubmit its apitegromab biologics license application after a previous FDA rejection.
The FDA approved Novartis' Itvisma, a gene replacement therapy for spinal muscular atrophy (SMA), which can treat patients two years and older by addressing the genetic root cause of the disease with a one-time fixed dose.
This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.
The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
